Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells.
Adams
Peter D
PD
Fox Chase Cancer Center; Philadelphia, Pennsylvania USA.
Cairns
Paul
P
D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D047628:Estrogen Receptor alpha; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D011960:Receptors, Estrogen / Q000096:biosynthesis* / Q000235:genetics
D004791:Enzyme Inhibitors; D047628:Estrogen Receptor alpha; D016376:Oligonucleotides, Antisense; D011960:Receptors, Estrogen; D000077209:Decitabine; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases; C000619380:DNMT1 protein, human; D001374:Azacitidine